Clinical Trial

Mosaic Mitral Valve: Long-Term Outcomes in Patients Under 65

Study acronym: MMV
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 20, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-31.
Trial Details
NCT Number NCT06917586
Lead Sponsor Michael Moront
Conditions Valve Disease, Heart, Valve Replacement, Valve Regurgitation, Mitral, Valve Heart Stenosis
Enrollment 300 participants
Start Date 2025-01-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-20